GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kodiak Sciences Inc (FRA:K27) » Definitions » Institutional Ownership

Kodiak Sciences (FRA:K27) Institutional Ownership : 17.59% (As of May. 11, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Kodiak Sciences Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Kodiak Sciences's institutional ownership is 17.59%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Kodiak Sciences's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Kodiak Sciences's Float Percentage Of Total Shares Outstanding is 65.56%.


Kodiak Sciences Institutional Ownership Historical Data

The historical data trend for Kodiak Sciences's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kodiak Sciences Institutional Ownership Chart

Kodiak Sciences Historical Data

The historical data trend for Kodiak Sciences can be seen below:

2023-06-30 2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31
Institutional Ownership 22.04 21.62 20.87 20.28 18.05 18.23 17.69 17.59 17.47 17.59

Kodiak Sciences Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Kodiak Sciences (FRA:K27) Business Description

Traded in Other Exchanges
Address
1200 Page Mill Road, Palo Alto, CA, USA, 94304
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.

Kodiak Sciences (FRA:K27) Headlines

No Headlines